Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events

NCT07694414 is registered in ClinicalTrials.gov with Inge Marie Svane as lead sponsor.

NCT NCT07694414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07694414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events
Lead sponsor
Inge Marie Svane
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
December 1, 2028
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune-related adverse events